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Abstract 
 
To examine psychiatric prescribing in response to perinatal/neonatal death, we analyzed 
data from a cross-sectional survey of 235 bereaved parents participating in an on-line 
support community. Of the 88 respondents prescribed medication, antidepressants were 
most common (n = 70, 79.5%) followed by benzodiazepines/sleep aids (n = 18, 20.5%). 
Many prescriptions were written shortly after the death (32.2% within 48 hours, 43.7% 
within a week, and 74.7% within a month). Obstetrician/gynecologists wrote most 
prescriptions given shortly after loss. Most respondents prescribed antidepressants took 
them long-term. This sample is select, but these data raise disturbing questions about 
prescribing practices for grieving parents.  
 
KEYWORDS: Stillbirth, bereavement, antidepressive agents, benzodiazepines, 
evidence-based medicine 
 
 Both stillbirth and perinatal/neonatal death are important global health issues 
(e.g., Froen, et al., 2011) that can cause both acute and enduring psychological distress in 
the bereaved. Experiencing a stillbirth puts women at increased risk of post-traumatic 
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stress disorder (PTSD), depression, and anxiety (Boyle, Vance, Najman, & Thearle, 
1996). A cohort study found that 29% of women met criteria for PTSD in pregnancy 
subsequent to stillbirth (Turton, Evans, & Hughes, 2009). Other studies have found an 
association between child death and anxiety, depression, psychiatric hospitalization, and 
completed suicide (e.g., Qin & Mortenson, 2011). 
 
 Faced with a patient in acute bereavement and with awareness of the potential for 
long-term psychological sequelae, clinicians have several options for meaningful 
intervention. Psychosocial care on the part of clinicians clearly has an important role, 
ideally including patient-centered psychosocial care (Cacciatore, 2010). Physicians can 
refer bereaved parents to support groups and/or to non-medical helping professionals for 
evidence-based psychotherapy (e.g., Shear, Frank, Houch, & Reynolds, 2005). However, 
there is a paucity of well-replicated interventional research for traumatic bereavement, 
raising the question of whether any of the currently available psychosocial interventions 
can be said to be evidence-based. 
 
 Psychiatric medications are another potential intervention, and physicians 
sometimes prescribe sedatives such as benzodiazepines (BZs) for bereavement. A survey 
of obstetricians found that roughly half believed that BZs could be a useful to bereaved 
parents who recently lost an infant (Gold, Schwenk, & Johnson, 2008; see also Cook, 
Biyanova, & Marshall, 2007). Only one randomized controlled trial (RCT) of BZs for 
acute bereavement has taken place (Warner, Metcalfe, & King, 2001). This small trial 
found no positive impact of BZs on either grief severity or sleep, and patients randomized 
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to diazepam reported more sleep problems. In a survey of the RCT participants, some 
opined that BZs could be helpful, but the majority also agreed that the prescription of BZ 
can “delay coming to terms with loss” (Warner et al., 2001, p. 40). None of the 
participants developed BZ dependence, likely due to the close monitoring within the 
RCT. However, the potential for short-term BZ use to lead to dependence remains a 
concern within real-world clinical practice (van Hulter, Teeuw, Bakker, & Leufkens, 
2003). Data suggesting that BZs are not helpful in the recently traumatized should also be 
considered (Gelpin, Bonnie, Peri, Brandes, & Shalev, 1996).   
 
 Antidepressant (AD) medications are also an option for the treatment of 
bereavement. There are several studies for both bereavement-related depression and 
complicated grief. The limitations of the evidence for antidepressants have been noted 
(Bui, Nadal-Viens, & Simon, 2012). The trials are small, not randomized, and/or 
demonstrate a statistically significant impact on symptoms of clinical depression, but no 
clinically important impact on grief severity or duration. Several open-label trials find a 
positive impact for ADs (Bui et al., 2012). However, psychopharmacological trials are 
easily confounded by the placebo effect (Kirsch, 2010) and confirmatory bias; without 
double-blind, randomized controlled trials, it is not possible to isolate the clinical impact 
of ADs from the potential presence of rater bias or expectancy effects (e.g., Gaudiano & 
Herbert, 2005) and especially problematic to assert that ADs are superior to other forms 
of clinical intervention, such as evidence-based psychotherapy.  
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 In short, at present, there exists no rigorous evidence to support the prescription of 
ADs in bereavement. Yet, it is common for ADs to be prescribed off-label for conditions 
which do not have supporting RCT evidence (e.g., McManus, Mant, Mitchell, Britt, & 
Dudley, 2003). Given the serenic-like effects of ADs (Glenmullen, 2000), they are likely 
to be prescribed to the bereaved. The positive effects must be carefully balanced with 
other issues, such as the overestimation of AD efficacy (Kirsch, 2010; Turner, Matthews, 
Linaradatos, Tell, & Rosenthal, 2008), the medicalization of grief (Moules, 1998), and 
the risk of adverse effects, including discontinuation syndrome (Gentile, 2011; Haddad, 
2001).  
 
 Distinct from the use of BZs, a prescription for an AD can be viewed as implicitly 
assuming that the patient is being treated for a long-term problem, and that short-term 
relief is not the goal. Selective serotonin reuptake inhibitors (SSRIs), the most-prescribed 
class of ADs, are generally not considered to provide a short-term benefit, often taking 
14-30 days to take full effect (Nirenberg et a., 2009). They are therefore inappropriate for 
short-term use. Treatment guidelines suggest that depressed patients complete ≥ 4-6 
months of treatment (e.g., American Psychiatric Association, 2000). Patients are more 
likely to discontinue ADs early when the prescriber is a non-psychiatrist and/or the 
diagnosis is not depression or anxiety (Pomerantz et al., 2004).  
 
 In terms of both evidence-based medicine and evidence-based psychosocial 
intervention, the interrelated issues of acute bereavement, psychiatric diagnosis 
(Horowitz & Wakefield, 2007) and timing of prescription are important to consider. If a 
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bereaved parent meets DSM-IV-TR criteria (American Psychiatric Association, 2000b) 
for major depression, then prescription of an SSRI could conceivably be supported by 
citing the RCT evidence. A recent Cochrane review finds a median Number-Needed-to-
Treat (NNT) of 7 for SSRIs prescribed for depression versus inactive placebo in primary 
care (Arroll et al., 2009). However, diagnosing a recently bereaved person with a mental 
disorder is controversial (e.g., Thieleman & Cacciatore, in press). 
 
 The DSM-IV-TR defined definition of Major Depression (MDD) requires clinically 
significant symptoms sustained for at least two weeks, at eight weeks post-loss. The 
DSM-IV-TR authorizes the application of the depression diagnosis before eight weeks 
when a client is experiencing “marked functional impairment, morbid preoccupation with 
worthlessness, suicidal ideation, or psychomotor agitation” (APA, 2000b, p. 356), but 
provides no guidance regarding a minimum amount of time required for such symptoms. 
This leads to obvious questions regarding the reliability and validity of such diagnoses in 
the recently bereaved − what one clinician may deem MDD, another may consider a 
normal grief reaction. Importantly, the benefits of ADs are unclear when prescribed to 
patients with an uncertain psychiatric diagnosis, or for contradicted indications such as 
“dysphoric complaints or demoralization” (Fava, 2003, p. 129).  
 
  The dilemma is similar when treating a bereaved person who shows signs of 
psychological trauma. SSRIs are used in PTSD (Asnis, Kohn, Henderson, & Brown, 
2004), the diagnosis of which requires more than one month of symptoms following the 
trauma (American Psychiatric Association, 2000b). The time period before diagnosis is 
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allowed reflects the fact that many traumatized individuals have acute reactions but do 
not go on develop PTSD (Yehuda, Mcfarlane, & Shalev, 1998). Similarly, the diagnosis 
of complicated grief proposed for DSM-5 (Shear, et al., 2011) requires that the bereaved 
individual be at no less than six months post-loss and have experienced significant 
impairment for the last month. 
 
Thus, the practice of prescribing ADs to bereaved individuals shortly after a loss is 
questionable. This is particularly true given that the intense clinical distress manifested 
immediately after a loss is often a poor predictor of long-term functioning (Neimeyer & 
Currie, 2009). Arguably, a conservative approach to prescribing, which would maximize 
benefit and minimize risk, would be to reserve ADs until it was clear that the patient met 
full criteria for MDD, PTSD, or, perhaps complicated grief as proposed for DSM-5. At 
present, though, there is a paucity of empirical data regarding psychiatric prescribing in 
response to perinatal/neonatal death, when diagnosis and prognosis are uncertain but 
patients are in significant clinical distress. 
 
The objective of this study was to describe patterns of psychiatric medication prescribing 
among parents who had experienced the perinatal/neonatal death of a child. Specifically, 
we examined the: (1) rate at which psychiatric medications were prescribed to deal with 
loss, and the types of medication used; (2) time lapse between loss and prescription 
across different prescriber specialties; (3) demographic and clinical variables associated 
with the prescription of medication; and (4) persistence of treatment. 
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METHOD 
Participants 
This study analyzes data from a cross-sectional on-line survey of bereaved parents 
participating in an on-line support community from 2009-2010. The survey methodology 
and description of the full sample are reported at length elsewhere (Cacciatore, Lacasse, 
Lietz & McPherson, in-press). The survey had a response rate of 51.75% (N = 503). 
There were 273 respondents who experienced perinatal/neonatal death at > 20 weeks 
gestation or lost their child ≤ 28 days after birth since calendar year 2000. Six did not 
answer the question on psychiatric medication, and, as we sought to assess prescription 
patterns in response to loss, we censored any cases taking psychiatric medication at the 
time of loss (n = 32), leaving 235 cases for analysis. 
 The majority of respondents were women (n = 227, 99.6%), had education 
beyond high school (n = 206, 87.7%), were Caucasian/White (n = 195, 82.3%) and had 
experienced an unexpected perinatal/neonatal death (n =  123, 52.3%), most frequently, a 
stillbirth (n = 168, 71.5%). Only a small proportion (n = 21, 8.7%) had been diagnosed 
with a mental disorder at the time of their loss. Of the 235 respondents, 88 (37.4%) had 
been prescribed psychiatric medication at some point in response to their loss.  
 
Measures 
Demographic And Clinical Variables 
 Each respondent completed a demographic questionnaire (age, race/ethnicity, education) 
as well as questions regarding the circumstances of the death of their child. We asked 
whether the child death had been a stillbirth, whether the death was expected, and at what 
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point in the pregnancy/neonatal period it took place. We also asked “In the months before 
the loss, were you diagnosed with any mental health condition?”, followed by a list of 
common mental health conditions. Respondents were also asked about their participation 
in professional counseling and support groups. 
 
 Self-Report Of Psychiatric Prescribing History 
Respondents were asked, “Have you ever been prescribed psychiatric medications to deal 
with your loss?”; those who answered affirmatively were piped to a series of detailed 
questions, including a list of prescribed medications, the specialty of the clinician who 
initially prescribed them, and the time delay between loss and prescription. Respondents 
were then asked if they were still on medications and asked to list them; if they were no 
longer on medication, we asked the date of discontinuation. 
 
 We classified prescriptions into the following discreet categories: No psychiatric 
prescription in response to loss; BZ /sleep aid only; antidepressant monotherapy only; or 
combination treatment. Combination treatment referred to the combination of two ADs or 
an AD plus an additional medication. Trazadone was classified as a sleep aid in all cases 
except for one, in which other available data suggested that it was prescribed for 
depression.  
 
Procedure 
 Pilot testing of survey questions among stakeholders helped refine the survey. 
Ethical approval was obtained from the Institutional Review Board of Arizona State 
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University, and the research committee of the participating nonprofit organization. A 
database of active forum participants from 2009-2010 was provided by the participating 
nonprofit, and participants were emailed an invitation to participate in the study by 
accessing an on-line Qualtrics survey. The survey instrument was lengthy and contained 
many instruments which are reported elsewhere, such as measures of mental health 
functioning (see Cacciatore, et al., in-press). To encourage participation, we followed up 
the initial request with an email reminder, a video message from the collaborating non-
profit, and finally, a solicitation offering a $20 gift card as incentive for participation. A 
cover letter informed participants that the study was voluntary and that data would only 
be reported in aggregate, anonymous form. The subgroup data analyses reported here 
focus on the prescribing of psychiatric medications and have not been reported 
elsewhere.   
 
RESULTS 
Frequency And Type Of Medication 
  Of the 88 bereaved parents who received medication, 20.5% (n = 18) received a 
prescription for BZ or sleep aid monotherapy, 39.8% (n = 35) received AD monotherapy, 
and 39.8% (n = 35) received treatment with a combination of psychiatric drugs. 
Combination treatment primarily consisted of AD + BZ and/or sleep aids (n = 23, 
26.1%). Four participants (4.5%) received a medication combination including an 
antipsychotic; two had a mental health diagnosis in the months preceding the loss. The 
most popularly prescribed antidepressants were sertraline, fluoxetine, and escitalopram, 
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while the most popular benzodiazepines were lorazepam and alprazolam, and zolpidem 
was the most frequently prescribed sleep aid.  
 
Medications By Prescriber Specialty And Time-Since-Loss 
 Prescriptions were cross-tabulated by time-to-prescription and specialty of the 
prescriber (see table 1). Medication was frequently prescribed shortly after the loss; 
32.2% (n = 28) were written within 48 hours, 43.7% (n = 38) within a week, and 74.7% 
(n = 65) within a month. Obstetricians/gynecologists wrote the majority of prescriptions 
written less than a month after loss (n = 46, 70.8%). Of the prescriptions written by 
OB/GYNs, 78.3% (n = 36) were for AD or combination therapy. Of those 36 bereaved 
parents receiving AD or combination treatment from their OB/GYN, nine reported that 
they were diagnosed with a mental disorder at the time of loss.  
 
Demographic And Clinical Variables Associated With Prescribing  
 We performed a series of exploratory logistic regressions performed using one 
block and forced entry, examining variables that might increase the odds of receiving a 
prescription for ADs. The odds ratio for a mental health diagnosis at the time of loss was 
3.66 (95% CI 1.04, 12.84, p = .043). All other variables examined (e.g., number of 
professional counseling sessions, support groups attended, stillbirth or not) did not reach 
statistical significance (Odds Ratios <1.04, p > .05 for all).  
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Persistence Of Treatment With Psychiatric Medication  
 Life table analysis was used to determine the median time-to-discontinuation for 
each category of medication (See figure 1). For this analysis, we collapsed the categories 
of antidepressant monotherapy and combination treatment. As respondents sometimes 
reported moderate changes in medication regimen across time (e.g., changing from 
fluoxetine monotherapy to fluoxetine + zolpidem), this allowed us to quantify the 
persistence of treatment while retaining most data for analysis. Respondents who made 
more notable medication switches are discussed below. We included all respondents 
prescribed psychiatric medication < 6 months after loss for which we had usable data on 
stop and start dates (n = 75). We constrained the life table analysis to 730 days (two 
years). 
 For AD/combination treatment, discontinuation rates were similar for both those 
prescribed within a week of loss (median = 539 days) and those > 1 week < 1 month 
(median = 523 days). Approximately half of respondents in both groups had discontinued 
treatment within one year. The subsample of those prescribed AD/combination treatment 
> 1 month after loss (n = 12) discontinued treatment much earlier, at a median of 294 
days, with only three such respondents (25%) continuing for the entire two-year period. 
For those prescribed BZs or sleep aid monotherapy within four weeks of loss (n = 14), 
the median time to discontinuation was 60 days; from day 300 forward, only one 
respondent continued the original BZ prescription.  
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Medication Status At Time Of Survey 
 Consistent with the life table analysis presented above, many respondents had 
discontinued their original medication, but some notable medication switches did occur 
(see table 2). The general trend otherwise was toward simplification of medication 
regimens; only 11 respondents were on multiple medications at the time of the survey 
(see table 2).  All respondents originally placed on antipsychotics reported that they had 
been discontinued. Of the 18 respondents originally prescribed BZ/sleep aid therapy, 15 
(83.3%) were off all medication; one remained on a benzodiazepine, and two had been 
switched to antidepressant monotherapy  
 
DISCUSSION 
In this cross-sectional survey of bereaved parents who suffered the perinatal/neonatal 
death of a child, we find that 37.4% (n =88) of the total sample (n = 235) have been 
prescribed medication to help deal with their loss. Most respondents who received 
medication were prescribed antidepressant (AD) medication (n = 70, 79.5% ) either as 
monotherapy or in combination with other medications. Most AD prescriptions were 
written < 4 weeks post-loss (n = 65, 73.9%), with OB/GYNs responsible for the largest 
proportion of AD prescriptions (n = 39, 44.8%). Many were written by OB/GYNs in the 
first week (n = 24, 27.6%), before these bereaved parents could have qualified for a 
diagnosis of PTSD or MDD, a questionable practice. 
 
However, we begin by cautioning against a rush to judgment toward the prescribers 
within our sample. We do not have data on the patient-clinician interactions, and 
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bereaved parents may have requested medication. In general, contemporary mental health 
treatment is focused on use of medication (Kirk, Gomory & Cohen, 2013). Both 
prescribers and patients in this sample have been subject to promotional efforts from 
pharmaceutical companies (i.e., Gomory, Wong, Cohen, & Lacasse, 2011) which may 
have shaped how they see mental distress and the role of psychiatric medication. Many 
prescribers undoubtedly do reach for the prescription pad too quickly, and the over-use of 
AD drugs in medicine is well-documented (e.g., Glenmullen, 2000). However, the rate of 
prescription found in this study- 29.8% receiving ADs in some form, and 7.7% receiving 
BZ or sleep aid monotherapy- should be seen in the context of contemporary psychiatric 
prescribing rates in other settings. In general practice, pseudopatients who reported 
depressive adjustment disorder symptoms were prescribed antidepressants 10% of the 
time when they did not directly request medication, and 39% of the time when they made 
a general request (Kravitz et al., 2005). As respondents had contact with prescribers who 
are no doubt familiar with ADs, it seems only fair to note that 62.6% of this sample (on 
average, ~3 years post-loss) were never prescribed medication to deal with their loss. 
Given the tragic nature of perinatal/neonatal death and the understandable inclination to 
do something to help, the prescribing practices observed here could be interpreted as 
reflecting therapeutic restraint. 
 
That said, our primary finding is that many respondents received AD prescriptions 
shortly after loss from their OB/GYNs. OB/GYNs wrote such prescriptions for 15 
patients (17.2%) within 48 hours of the death of a child, and for 24 patients (27.6%) 
within a week. There were only two other such prescriptions reported in the first week; 
D
ow
nl
oa
de
d 
by
 [2
4.1
21
.71
.74
] a
t 1
1:5
3 1
4 F
eb
ru
ary
 20
14
 
ACCEPTED MANUSCRIPT 
ACCEPTED MANUSCRIPT 
14
one by a psychiatrist, the other by a primary care physician to a respondent previously 
diagnosed with multiple mental disorders. OB/GYNs thus prescribed 84.6% (n = 11) of 
all AD monotherapy and 100% (n = 13) of all combination therapy prescribed within 
seven days. One week of clinical symptoms is not sufficient for a DSM-IV-TR diagnosis 
of MDD or PTSD, and thus 60% (n = 24) of AD prescriptions written by OB/GYNs were 
for patients who could not have met diagnostic criteria for PTSD or MDD.  
 We know of no method through which a prescriber could reliably ascertain, so quickly, 
whether a recently bereaved parent would develop a sustained clinical problem best 
treated through ADs. Yehuda et al. (1998) examined clinical symptoms in response to 
trauma longitudinally. They found similar reactions for all patients at two days post-
trauma, which separated a bit at day ten, with clear separation between no disorder, 
PTSD, depression and anxiety at six months. Such data suggests that prescribers simply 
cannot know the prognosis of acute bereavement. Indeed, awareness of such data may be 
one reason why the overall rate of prescribing was low. However, when ADs are 
prescribed shortly after loss, the purpose is essentially prophylaxis, which has been 
characterized as an overuse of AD medication (Conti, Bush and Cutler, 2011; Leo & 
Lacasse, 2010). Assuming that ADs can only have positive effects in this context would 
seemingly be naïve, especially given emerging data on the complicated risk-benefit 
calculus regarding use of psychiatric medication (Whitaker, 2010). 
 
AD prescriptions often resulted in long-term treatment. Most strikingly, roughly half of 
those prescribed AD medication within a week of losing their child were still taking them 
two years later. Although BZs have a reputation for causing dependence, there is 
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increasing recognition of an AD discontinuation syndrome that is of clinical concern (see 
Healy, 2004). If avoiding long-term treatment with psychiatric medication is seen as 
preferable, the small subsample prescribed BZ/sleep aid therapy fared best. Almost all 
discontinued treatment rapidly and only one respondent took BZs long-term. 
 
The use of SSRIs in women of childbearing age is also noteworthy, especially when 
prescribed without first exhausting psychosocial treatment options.  SSRI use in 
pregnancy is associated with a long list of obstetrical problems, such as miscarriage, 
preterm birth and low birth weight (Urato, 2011, p. 190). The odds ratio for congenital 
heart defects among women exposed to SSRIs in the first trimester of pregnancy is 2.01 
(95% CI, 1.53, 2.72) which suggests that ADs should be used conservatively among 
fertile women (Jiminez-Solem et al., 2012).  
 
Our data are retrospective, observational data reached through a cross-sectional self-
report. We did not have access to clinical documentation, respondents could have made 
errors in their recollection of past events. There were no data collected on clinical 
interactions, and we did not ask bereaved parents if they requested medication. We 
surveyed participants in an on-line support community, a group that may differ from the 
larger population of bereaved parents. While the on-line support group was not oriented 
around the use of medication, selection bias remains a concern, and these findings should 
be replicated in other samples. Finally, these data were collected under the DSM-IV-TR, 
and the impending DSM-5 removes the bereavement exclusion (Thieleman & Cacciatore, 
2013). However, our results have a similar interpretation under DSM-5, which requires 
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two weeks of symptoms to diagnosis MDD, and also cautions the clinician to consider 
context (bereavement) before diagnosing MDD. 
 
Most respondents did not receive psychiatric medication, and among those that did, it 
seems likely that it was thought of as an early intervention strategy. While early 
intervention may have appeal to prescribers, the potential for unintended consequences 
should be considered. To draw a parallel from the psychological literature, immediate 
debriefing after trauma has been a frequently used intervention. The idea that immediate 
intervention could prevent PTSD seems commonsensical. However, careful analysis of 
intervention data showed that those receiving debriefing fared no better, and possibly 
worse, than those receiving no treatment at all. Some hypothesized that debriefing 
interferes with natural coping mechanisms (McNally, Bryant, & Ehlers, 2003). Treatment 
guidelines now recommend against universal use of debriefing (Forbes et al., 2010). 
While the use of ADs in bereavement differs because of the lack of RCT data to settle the 
question, the debriefing example should give us pause. We do not know that AD 
treatment shortly after child death is helpful, and it could be harmful (Whitaker, 2010).  
 
CONCLUSION 
A recent editorial in The Lancet stated, “Medicalising grief, so that treatment is 
legitimized routinely with antidepressants, for example, is not only dangerously 
simplistic, but also flawed. The evidence base for treating recently bereaved people with 
standard antidepressant regimens is absent” (p. 589). Thus, our findings should be 
disturbing. If intervention is needed in bereavement, there are many options beyond the 
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use of psychopharmacology (e.g., Cacciatore & Flint, 2012). Improving psychiatric 
practice in traumatic bereavement – especially among OB/GYNs who may reach for the 
prescription pad too quickly- has the potential to significantly improve care, and perhaps 
outcomes, for bereaved parents. We are concerned that current practices have the 
potential to cause harm, and hope the field can move toward a more evidence-based use 
of psychiatric medication.  
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Table 1 Time Delay Until Prescription by Medical Specialty (N = 87) 
Note: Numbers in superscript (e.g.,(1)) represent the number of cases in each cell that 
were diagnosed with anxiety, depression, PTSD, or multiple diagnoses at the time of loss.  
BZ = benzodiazepine; OB/GYN = obstetrician/gynecologist; PC = Primary care; Psych = 
psychiatrist. Numbers of prescriptions in boldface were written < 4 weeks post-loss. One 
case had missing data. 
a Represents 12 prescriptions for benzodiazepines, two for zolpidem, two for “other 
sedative,” and one for trazadone 
b Represents one cardiologist and one neurologist  
Medication Specialty 0-2 
days 
3-7 
days
1-4 
week
1-2 
months
2-3 
month
3-6 
month
>6 
month
Total 
BZ monotherapya OB/GYN 9 1 0 0 0 0 0 10 
 PC 2 0 1 0 0 0 1 4
 Psych 0 0 2(2) 0 0 0 1 3
Antidepressant OB/GYN 6(2) 5(1) 5 0 1 0 0 17 
 PC 1(1) 0 3(2) 2 0 2 4(1) 12
 Psych 1 0 2(1) 0 0 0 1 4
 Otherb 0 0 0 0 1 0 1 2
Combination OB/GYN 9(2) 4 7 1 1 0 0 22 
 PC 0 0 2 1 1 0 2 6
 Psych 0 0 5 2(2) 0 0 0 7
Total  28 10 27 6 4 2 10 87 
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Table 2 Medication Status at Time of Survey by Initial Prescription Pattern 
Medication status at survey      Initial prescription   
 BZ&sol;Slee
p 
monotherapy
Antidepressant 
monotherapy 
Combination 
therapy 
Total  
 n % n % n % n % 
No medication to deal with loss 15 17.0 19 21.6 22 25.0 56 63.6 
BZ monotherapy 1 1.1 0  0  1 1.1 
Sleep aid monotherapy 0  0  0  0  
AD monotherapy 2 2.2 13 14.8 8 9.0 23 26.1 
Combination therapy 0  3 3.5 3 3.5 6 6.8 
 2 antidepressants   2 2.4     
 AD + BZ     1 1.2   
 AD + sleep aid     1 1.2   
 AD + psychostimulant   1 1.2     
Total 18 20.5 38 43.2 35 39.8 86 97.8 
 
Note: Two cases had missing data on these variables, thus these frequencies do not sum 
to 100%. 
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Figure 1. Life table analysis plotting persistence of initial treatment with psychiatric 
medication prescribed in response to perinatal/neonatal death, within 6 months of loss, by 
prescription pattern, from day 1-730. To aid in visual interpretation, the trajectories have 
been smoothed by presenting them in straight line rather than stepped format. For 
BZ/sleep aid <1 month, n = 14; for AD/combination treatment in first week, n = 27; for 
AD/combination treatment > 1 week < 1 month, n = 22; for AD/combination treatment 
>1 month, n = 12. 
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